In a nutshell, our discovery disclosed that ARHGAP39 activated the cell cycle and illustrated the drug interactions in patients, making it conducive to assisting the therapy of HCC patients to a certain extent. The gene discussed is ARHGAP39; the disease is hepatocellular carcinoma.